RSB expands US market for VBR (vertebral body replacement) tech:
This article was originally published in Clinica
The US FDA has given RSB Spine the market go-ahead to expand the indication of its InterPlate vertebral body replacement (VBR) system by allowing the product to be used without supplemental fixation. Under the new indication, the device can be used in patients where a less invasive, anterior approach is selected, in conjunction with a standalone implant. The Cleveland, Ohio firm said that compared to use with posterior supplemental fixation, the patient will recover more rapidly, and hospitals will realise "significant" cost savings. It added that marketing submissions for cervical and lumbar interbody indications are expected to follow, as well as new product designs based on the InterPlate platform.